Document is current
Any future updates will be listed below
-
Authors
Jackson, Rosemary J.
Melloni, Alexandra
Fykstra, Dustin P.
Serrano-Pozo, Alberto
Shinobu, Leslie
Hyman, Bradley T. https://orcid.org/0000-0002-7959-9401
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (Bristol-Myers Squibb)
National Institute on Aging (P30AG062421)
Rainwater Charitable Foundation (Rainwater Charitable Foundation)
Harrison Gardner, Jr. Innovation Award (Harrison Gardner, Jr. Innovation Award)
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 31 July 2024
First Online: 14 August 2024
Declarations
:
: Human brain tissues were collected with written informed consent of patients or their next-of-kin and under approval of the institutional review board at Massachusetts General Hospital.
: Not applicable.
: Dr. Hyman has a family member who works at Novartis and owns stock in Novartis; he serves on the SAB of Dewpoint and of Latus, and owns stock. He serves on a scientific advisory board or is a consultant for AbbVie, Ambagon, Aprinoia Therapeutics, Arvinas, Avrobio, Biogen, BMS, Cure Alz Fund, Cell Signaling, Dewpoint, Latus, Novartis, Sofinnova, Vigil, Violet, Voyager, WaveBreak. His laboratory is supported by research grants from the National Institutes of Health, Cure Alzheimer’s Fund, Tau Consortium, and the JPB Foundation – and sponsored research agreements from Abbvie, BMS, and Biogen. Dr. Shinobu is an employee of Bristol Myers Squibb (BMS) and owns stock in BMS and Voyager Tx. Dr. Serrano-Pozo has a material transfer agreement with Ionis Pharmaceuticals, Inc. to use antisense oligonucleotides in mouse models of AD.
